BCG immunotherapy for superficial bladder cancer - PubMed (original) (raw)

Review

BCG immunotherapy for superficial bladder cancer

C R Lockyer et al. J R Soc Med. 2001 Mar.

No abstract available

PubMed Disclaimer

Comment in

• BCG immunotherapy for superficial bladder cancer.
  Lane T. Lane T. J R Soc Med. 2001 Jun;94(6):316. doi: 10.1177/014107680109400630. J R Soc Med. 2001. PMID: 11387435 Free PMC article. No abstract available.

Similar articles

• Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
  Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR. Herr HW, et al. Urology. 1985 Feb;25(2):119-23. doi: 10.1016/0090-4295(85)90525-4. Urology. 1985. PMID: 3881870 Clinical Trial.
• Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
  Catalona WJ, Ratliff TL. Catalona WJ, et al. Surg Annu. 1990;22:363-78. Surg Annu. 1990. PMID: 2408170 Review. No abstract available.
• BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
  van der Meijden PM, Debruyne FM, Steerenberg PA, de Jong WH, Doesburg W. van der Meijden PM, et al. Prog Clin Biol Res. 1989;310:285-98. Prog Clin Biol Res. 1989. PMID: 2505272 Clinical Trial. No abstract available.
• [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
  Ackermann D, Schnyder M, Bandelier D, Studer UE. Ackermann D, et al. J Urol (Paris). 1986;92(1):33-8. J Urol (Paris). 1986. PMID: 3722851 French.

Cited by

• Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer.
  Lou K, Feng S, Zhang G, Zou J, Zou X. Lou K, et al. Front Oncol. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. eCollection 2022. Front Oncol. 2022. PMID: 35669417 Free PMC article. Review.
• Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette-Guérin.
  Kim JH, Lee S, Kang SJ, Choi YW, Choi SY, Park JY, Chang IH. Kim JH, et al. Int J Mol Sci. 2021 Aug 18;22(16):8887. doi: 10.3390/ijms22168887. Int J Mol Sci. 2021. PMID: 34445591 Free PMC article.
• Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
  Seo WI, Lee CH, Jung SJ, Lee DS, Park HY, Jeong DH, Kim W, Chung JI, Choi I. Seo WI, et al. Cancer Immunol Immunother. 2021 Nov;70(11):3113-3122. doi: 10.1007/s00262-021-02906-7. Epub 2021 Mar 26. Cancer Immunol Immunother. 2021. PMID: 33770210 Free PMC article.
• Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage.
  Severino PF, Silva M, Carrascal M, Malagolini N, Chiricolo M, Venturi G, Astolfi A, Catera M, Videira PA, Dall'Olio F. Severino PF, et al. Oncotarget. 2017 Apr 17;8(33):54506-54517. doi: 10.18632/oncotarget.17138. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903359 Free PMC article.
• Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.
  Lukacs S, Tschobotko B, Szabo NA, Symes A. Lukacs S, et al. Case Rep Urol. 2013;2013:821526. doi: 10.1155/2013/821526. Epub 2013 Jun 17. Case Rep Urol. 2013. PMID: 23844314 Free PMC article.

References

1. 1. J Urol. 1991 Jan;145(1):131-4 - PubMed
2. 1. Cancer Res. 1992 Jan 15;52(2):428-36 - PubMed
3. 1. J Urol. 1991 Jul;146(1):32-5 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information